TRT and Hematocrit: Why Testosterone Thickens the Blood, and What to Do About It

Of every laboratory change testosterone therapy can cause, one shows up more reliably than any other: the blood gets thicker. Hematocrit — the fraction of blood volume made up of red cells — and its companion hemoglobin climb in a large share of men who start treatment, and a meaningful minority cross into the range clinicians call erythrocytosis (or, loosely, polycythemia).^[1] The honest framing is neither alarmist nor dismissive: this is the most common adverse effect of testosterone therapy, it is largely predictable from the dose and the delivery route, and it is manageable when someone is actually watching for it. The problem is almost never the rise itself. It is the rise that goes unmonitored.

Why testosterone thickens the blood

Testosterone is an erythropoietic hormone. Exogenous testosterone stimulates erythropoiesis through more than one channel: it raises erythropoietin (EPO), the kidney hormone that drives red-cell production, and it suppresses hepcidin, the master regulator of iron. Lower hepcidin frees up more iron for incorporation into new red cells, so the marrow has both the signal and the raw material to expand red-cell mass.^[2] The net effect is a measurable increase in red-cell count, hemoglobin, and hematocrit over the first months of therapy. This is a class effect of androgen exposure rather than a quirk of any single product.

The most common lab change on therapy

Pooled analyses of randomized trials put erythrocytosis at the top of the testosterone adverse-event list. A systematic review and meta-analysis of testosterone trials found that treated men were significantly more likely than placebo-treated men to develop an elevated hematocrit, and that this was the most consistent testosterone-attributable lab abnormality across studies.^[3]It is worth being precise about what that means: a statistically robust, dose-related shift in a number, not an automatic clinical catastrophe. The clinical question — whether the thicker blood actually harms people — is separate, and we treat it below.

Route and formulation change everything

The single biggest modifiable driver of how high hematocrit goes is how the testosterone is delivered. Short-acting intramuscular injections produce supraphysiologic peaks in the days after a dose, and those peaks appear to do more to stimulate erythropoiesis than the steadier levels from transdermal gels or patches. Across the evidence, injectable testosterone raises hematocrit and triggers erythrocytosis more often than transdermal preparations.^[4] Higher peak concentrations, higher overall dose, and longer dosing intervals (which create bigger peak-to-trough swings) all push the same direction. This is why a man who develops a borderline-high hematocrit on weekly intramuscular testosterone may normalize simply by splitting the dose, lowering it, or switching to a transdermal route — the hormone exposure changes shape, and so does the marrow's response.

The thresholds and what guidelines say

Both major specialty guidelines treat hematocrit as a mandatory safety parameter rather than an optional one. The Endocrine Society clinical practice guideline recommends measuring hematocrit at baseline, and advises against starting testosterone in a man whose baseline hematocrit is already above 50%. It sets an action threshold during therapy at a hematocrit above 54%, at which point treatment should be stopped until the level falls and the cause is evaluated, then restarted at a reduced dose.^[5] The American Urological Association guideline likewise directs clinicians to measure hemoglobin and hematocrit before offering therapy and to counsel patients about the increased risk of polycythemia.^[6] The numbers are not arbitrary precision — they are pragmatic lines that flag when the balance of benefit and risk has tipped and a change is warranted.

Does the thicker blood actually cause harm?

This is where honesty matters most, because the intuition — thicker blood, therefore more clots — is plausible but not fully proven. The large TRAVERSE trial randomized middle-aged and older men with hypogonadism and cardiovascular risk to transdermal testosterone or placebo and found that testosterone was non-inferior to placebo for the primary composite of major adverse cardiovascular events.^[7]That is the reassuring headline. The fine print is less tidy: TRAVERSE recorded higher rates of certain events in the testosterone group, including atrial fibrillation, acute kidney injury, and pulmonary embolism.^[7] The trial used a transdermal product precisely because it raises hematocrit less, so it does not directly answer what happens at the higher hematocrits common with injectable regimens. The defensible reading: medically indicated testosterone did not raise overall cardiovascular event rates in this population, but the venous thromboembolism and arrhythmia signals are reasons to monitor, not to wave the risk away.

How erythrocytosis is managed

When hematocrit climbs into the action range, the response is a ladder rather than a single move. The first steps address the cause: reduce the testosterone dose, shorten the dosing interval to flatten the peaks, or switch from an injectable to a transdermal formulation — each of which lowers the erythropoietic drive at its source.^[4] For a hematocrit that is already markedly elevated or symptomatic, therapeutic phlebotomy — removing a unit of blood — brings the number down quickly, and case series describe it as an effective way to keep men on therapy whose hematocrit would otherwise force a stop.^[8]Holding testosterone entirely is reserved for hematocrits above the guideline threshold or when other measures fail.^[5] It is also worth ruling out contributors that have nothing to do with testosterone — smoking, untreated sleep apnea, and dehydration all raise hematocrit on their own and can be the real lever.

A sensible monitoring cadence

The mechanism makes the schedule obvious: catch the rise while it is still small. Guidelines converge on measuring hematocrit at baseline before starting, again at roughly three to six months once levels have stabilized, and then at least annually for as long as therapy continues — with more frequent checks after any dose increase or formulation change.^[5][6] A baseline value is not optional: it both screens out men who should not start and gives the reference point that makes a later reading interpretable.

The honest verdict

Hematocrit rise on testosterone therapy is real, expected, and the most common adverse effect of treatment — not a rare surprise. Its magnitude is largely under the prescriber's control through dose and route, with injectable testosterone the heaviest driver and transdermal the gentlest.^[4] Whether the thicker blood translates into clots or cardiovascular events is not fully settled; the best randomized evidence is broadly reassuring on overall cardiovascular risk while flagging venous thromboembolism and arrhythmia signals worth respecting.^[7] The practical conclusion is unglamorous and correct: erythrocytosis is a managed, monitorable consequence of therapy, and for a man with a genuine indication it is a reason to check the blood count on a schedule — not a reason to forgo treatment that is otherwise warranted.